Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation

Table 2

Positive samples among all investigated samples from patients with COVID-19 stratified according to time of serum sampling since the first clinical presentation. Positivity rates are given in brackets.

	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
LFIA IgG	14/34; (41%)	14/31; (45%)	14/18; (78%)	15/19; (79%)	14/18; (78%)	16/25; (64%)	29/38; (76%)	18/32; (56%)	5/7; (71%)
LFIA IgM	18/34; (53%)	23/31; (74%)	14/18; (78%)	14/19; (74%)	11/18; (61%)	8/25; (32%)	15/38; (39%)	8/32; (13%)	2/7; (29%)
LFIA IgG/IgM	19/34; (56%)	24/31; (77%)	16/18; (89%)	16/19; (84%)	15/18; (83%)	18/25; (72%)	31/38; (82%)	19/32; (59%)	6/7; (86%)
EI ELISA IgG	11/23; (48%)	7/19; (37%)	6/6; (100%)	9/10; (90%)	16/17; (94%)	23/26; (88%)	35/39; (90%)	32/38; (84%)	39/40; (98%)
EI ELISA IgA	11/23; (48%)	12/19; (63%)	6/8; (75%)	9/10; (90%)	14/15; (93%)	21/26; (81%)	32/38; (84%)	29/38; (76%)	13/16; (81%)
EDI ELISA IgG	24/35; (69%)	24/32; (75%)	20/20; (100%)	28/28; (100%)	27/30; (90%)	28/35; (80%)	36/47; (77%)	26/37; (70%)	14/24; (58%)
EDI ELISA IgM	21/35; (60%)	17/32; (53%)	19/20; (95%)	11/26; (42%)	13/30; (43%)	9/35; (31%)	15/47; (32%)	6/37; (16%)	3/24; (13%)
ECLIA Ig	21/34; (62%)	18/26; (69%)	19/19; (100%)	20/21; (95%)	28/29; (97%)	32/34; (94%)	44/45; (98%)	37/39; (95%)	49/53; (92%)
CMIA IgG	19/31; (61%)	17/28; (61%)	18/18; (100%)	21/22; (95%)	27/28; (96%)	31/32; (97%)	40/43; (93%)	33/36; (92%)	12/13; (92%)
LIA IgG	17/32; (53%)	14/28; (50%)	16/18; (89%)	18/21; (86%)	26/28; (93%)	27/32; (84%)	42/44; (95%)	32/38; (84%)	24/26; (92%)